Source:http://linkedlifedata.com/resource/pubmed/id/18022579
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0005953,
umls-concept:C0009450,
umls-concept:C0009566,
umls-concept:C0010825,
umls-concept:C0018133,
umls-concept:C0021079,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0039194,
umls-concept:C0332293,
umls-concept:C0333668,
umls-concept:C0445356,
umls-concept:C0851807,
umls-concept:C0936012,
umls-concept:C1550587,
umls-concept:C1709854
|
| pubmed:issue |
12
|
| pubmed:dateCreated |
2007-11-20
|
| pubmed:abstractText |
Serious infections are a major obstacle limiting the usefulness of unrelated donor marrow transplantation. Graft-versus-host disease (GVHD) and its therapy are associated with a high risk of opportunistic infection. In this study, patients were randomized to receive 1 of 2 GVHD prophylaxis strategies, marrow T cell depletion, and cyclosporine (TCD) or methotrexate/cyclosporine (M/C) after transplantation. The patients underwent transplantation between March 1995 and October 2000 as part of a multicenter randomized trial. As a secondary analysis, we analyzed infections in this study cohort. Among the 404 patients who underwent transplantation, a total of 1598 infections were reported. The rates of serious and fatal infections did not differ between the TCD and M/C groups. Bacterial infections accounted for 1/3 of serious infections in each treatment arm. A significantly higher incidence of severe cytomegalovirus (CMV) and life-threatening or fatal aspergillus infections was observed in the patients receiving TCD (CMV, 28% vs 17% [P = .02]; aspergillosis, 16% vs 7% [P < .01]). The only independent risk factor for serious infection was the development of grade III-IV acute GVHD (aGVHD; hazard ratio = 1.41; 95% confidence interval = 1.03-1.91). Strategies to speed immune recovery, even in the absence of GVHD, are needed to overcome the risk of infection after unrelated donor transplantation.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1083-8791
|
| pubmed:author |
pubmed-author:CarterShelly LSL,
pubmed-author:FreifeldAlison GAG,
pubmed-author:GodderKamar TKT,
pubmed-author:HighKevin PKP,
pubmed-author:KernanNancy ANA,
pubmed-author:MendizabalAdam MAM,
pubmed-author:PapanicolaouGenovefa AGA,
pubmed-author:WagnerJohn EJE,
pubmed-author:YanovichSaulS,
pubmed-author:van BurikJo-Anne HJA
|
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1487-98
|
| pubmed:meshHeading |
pubmed-meshheading:18022579-Adolescent,
pubmed-meshheading:18022579-Adult,
pubmed-meshheading:18022579-Aspergillosis,
pubmed-meshheading:18022579-Bone Marrow Transplantation,
pubmed-meshheading:18022579-Cohort Studies,
pubmed-meshheading:18022579-Cyclosporine,
pubmed-meshheading:18022579-Cytomegalovirus Infections,
pubmed-meshheading:18022579-Female,
pubmed-meshheading:18022579-Graft vs Host Disease,
pubmed-meshheading:18022579-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:18022579-Humans,
pubmed-meshheading:18022579-Immunosuppression,
pubmed-meshheading:18022579-Immunosuppressive Agents,
pubmed-meshheading:18022579-Incidence,
pubmed-meshheading:18022579-Lymphocyte Depletion,
pubmed-meshheading:18022579-Male,
pubmed-meshheading:18022579-Methotrexate,
pubmed-meshheading:18022579-Opportunistic Infections,
pubmed-meshheading:18022579-Retrospective Studies,
pubmed-meshheading:18022579-Survival Analysis,
pubmed-meshheading:18022579-Transplantation, Homologous
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
|
| pubmed:affiliation |
Department of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota, USA. vanbu004@umn.edu
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Research Support, N.I.H., Extramural
|